News

May 20, 2024

A Success at the HKTDC Hong Kong International Medical and Healthcare Fair: Our Team Delivered a Presentation Titled ‘Choice Is Power: BYQM’s Cancer Therapy Decision Aid, Offering Expanded Options for Cancer Patients.’

May 1, 2024

Visit Us at Booth 3E-D07 During the HKTDC Hong Kong International Medical and Healthcare Fair, May 16-18, 2024, at the Hong Kong Convention and Exhibition Centre, Wan Chai.

Nov 30, 2023

Significant Success: Prof. Benjamin Yung Delivered an Insightful and Impactful Presentation on ‘Mission Possible: NPM/B23 Gene Co-Expressions Uncovering the Origins of Cancer (All Diseases)’ in November 2023 at the Department of Bioscience Technology, Chung Yuan Christian University, Taipei.

Nov 1, 2023

Exciting Announcement: The Enterprise Support Scheme (ESS) of the Innovation and Technology Fund (ITF) Has Approved Funding for Our Project Titled ‘Developing a Quantitative Gene Co-Expression Test (QGCT) for Chemoresistance in High-Grade Serous Ovarian Cancer (HGSOC)’ as of November 1, 2023.

Jun 26, 2023

We Are Pleased to Announce That We Have Received a Written Opinion from the International Search Authority of the Patent Cooperation Treaty (PCT).

May 10, 2022

6th International Conference on the Modernization of Traditional Chinese Medicine

Publications

Benjamin Yat Ming Yung, (underlined), corresponding author, major author, work of his graduate students or research associates, collaborative partners and colleagues under his supervision and guidance.

Protein B23 Translocation
  1. Yung BYM*, Busch RK, Busch H, Mauger AB, Chan PK (1985) Effects of actinomycin D analogs on nucleolar phosphoprotein B23 (37,000 daltons/pI 5.1). Biochem Pharmacol 34: 4059-4063. Impact Factor: 4.581

  2. Yung BYM*, Busch H, Chan PK (1985) Translocation of nucleolar phosphoprotein B23 (37 kDa/pI 5.1) induced by selective inhibitors of ribosome synthesis. Biochim Biophys Acta 826: 167-173. Impact Factor: 4.521

  3. Yung BYM*, Busch H, Chan PK (1986) Effects of luzopeptins on protein B23 translocation and ribosomal RNA synthesis in HeLa cells. Cancer Res 46: 922-925. Impact Factor: 122

  4. Chan PK, Aldrich MB, Yung BYM (1987) Nucleolar protein B23 translocation after doxorubicin treatment in murine tumor cells. Cancer Res 47: 3798-3801. Impact Factor: 9.122

  5. Yung BYM, Bor AM, Chan PK (1990) Short exposure to actinomycin D induces “reversible” translocation of protein B23 as well as “reversible” inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res 50: 5987-5991. Impact Factor: 9.122

  6. Yung BYM, Bor AM, Yang YH (1990) Immunolocalization of phosphoprotein B23 in proliferating and non-proliferating HeLa cells. Int J Cancer 46: 272-275. Impact Factor: 6.513

  7. Yung BYM, Yang YH, Bor AM (1991) Nucleolar protein B23 translocation after deferoxamine treatment in a human leukemia cell line. Int J Cancer 48: 779-784. Impact Factor: 6.513

  8. Yung BYM, Chang FJ, Luo KJ (1991) Dipyridamole enhancement of doxorubicin-induced translocation of nucleophosmin and inhibition of cell growth in HL-60 cells. Int J Cancer 49: 592-597. Impact Factor: 6.513

  9. Yung BYM, Chang FJ, Bor AM (1991) Modulation of the reversibility of actinomycin D cytotoxicity in HeLa cells by verapamil. Cancer Lett 60: 221-227. Impact Factor: 6.375

  10. Yung BYM, Bor AM (1992) Identification of high-density lipoprotein in serum to determine anti-cancer efficacy of doxorubicin in HeLa cells. Int J Cancer 50: 951-957. Impact Factor: 6.375

  11. Yung BYM, Chang FJ, Bor AM, Lee ES (1992) Schedule-dependent effects of two consecutive, divided, low doses of actinomycin D on translocation of protein B23, inhibition of cell growth and RNA synthesis in HeLa cells. Int J Cancer 52: 317-322. Impact Factor: 6.513

  12. Bor AM, Chang FJ, Yung BYM (1992) Phosphoprotein B23 translocation and modulation of actinomycin D and doxorubicin cytotoxicity by dipyridamole in HeLa cells. Int J Cancer 52: 658-663. Impact Factor: 6.513

  13. Wu MH, Lam CY, Yung BYM (1995) Translocation of nucleophosmin from nucleoli to nucleoplasm requires ATP. Biochem J 305 (Pt 3): 987-992. Impact Factor: 3.797
  1. Hui EK, Yang YH, Yung BYM (1992) Schedule-dependent sphinganine potentiation of retinoic acid-induced differentiation, cell growth inhibition, and nucleophosmin translocation in a human leukemia cell line (HL-60). Exp Hematol 20: 454-461. Impact Factor: 2.820

  2. Wei LL, Hui EK, Wei JS, Yung BYM (1992) Alkaline phosphatase activity during differentiation of the human promyelocytic leukemia cell line, HL-60. Biochem Biophys Res Commun 182: 487-494. Impact Factor: 2.466

  3. Yung BYM, Luo KJ, Hui EK (1992) Interaction of antileukemia agents adriamycin and daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60. Cancer Res 52: 3593-3597. Impact Factor: 9.122

  4. Hui EK, Yung BYM (1992) Protein kinase C activity during sphinganine potentiation of retinoic acid-induced differentiation in a human leukemia cell line (HL-60). Life Sci 51: 415-422. Impact Factor: 2.936

  5. Hui EK, Yung BYM (1993) Cell cycle phase-dependent effect of retinoic acid on the induction of granulocytic differentiation in HL-60 promyelocytic leukemia cells. Evidence for sphinganine potentiation of retinoic acid-induced differentiation. FEBS Lett 318: 193-199. Impact Factor: 3.902

  6. Wei LL, Hui EK, Wei JS, Tzeng WF, Yung BYM (1993) Alkaline phosphatase activity during sphinganine potentiation of retinoic acid-induced differentiation of human promyelocytic leukemia cell line, HL-60. Life Sci 52: 2035-2043. Impact Factor: 2.936

  7. Yung BYM, Hui EK (1993) Differential regulation of protein kinase C isoenzymes during sphinganine potentiation of retinoic acid-induced granulocytic differentiation in human leukemia HL-60 cells. Biochem Biophys Res Commun 196: 1390-1400. Impact Factor: 2.466

  8. Wu MH, Yung BYM (1994) Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells. Eur J Pharmacol 270: 203-212. Impact Factor: 2.896

  9. Yung BYM, Hsiao TF, Wei LL, Hui EK (1994) Sphinganine potentiation of dimethyl sulfoxide-induced granulocyte differentiation, increase of alkaline phosphatase activity and decrease of protein kinase C activity in a human leukemia cell line (HL-60). Biochem Biophys Res Commun 199: 888-896. Impact Factor: 2.466

  10. Yung BYM (1994) Sphinganine potentiation of cellular differentiation induced by various anti-leukemia drugs in human leukemia cell line HL-60. Naunyn Schmiedebergs Arch Pharmacol 350: 575-581. Impact Factor: 2.558

  11. Yung BYM, Hui EK (1995) Differential cellular distribution of retinoic acid during staurosporine potentiation of retinoic acid-induced granulocytic differentiation in human leukemia HL-60 Cells. J Biomed Sci 2: 154-159. Impact Factor: 2.799

  12. Wei L, Yung BYM (1995) Effects of okadaic acid and vanadate on TPA-induced monocytic differentiation in human promyelocytic leukemia cell line HL-60. Cancer Lett 90: 199-205. Impact Factor: 6.375

  13. Kuo CL, Chou CC, Yung BYM (1995) Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett 93: 193-200. Impact Factor: 6.375

  14. Chou CC, Lam CY, Yung BYM (1995) Intracellular ATP is required for actinomycin D-induced apoptotic cell death in HeLa cells. Cancer Lett 96: 181-187. Impact Factor: 6.375

  15. Chou YH, Yung BYM (1995) Cell cycle phase-dependent changes of localization and oligomerization states of nucleophosmin / B23. Biochem Biophys Res Commun 217: 313-325. Impact Factor: 2.466

  16. Lu YY, Lam CY, Yung BYM (1996) Decreased accumulation and dephosphorylation of the mitosis-specific form of nucleophosmin/B23 in staurosporine-induced chromosome decondensation. Biochem J 317 (Pt 1): 321-327. Impact Factor: 3.797

  17. Chang ST, Yung BYM (1996) Potentiation of sodium butyrate-induced apoptosis by vanadate in human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 221: 594-601. Impact Factor: 2.466

  18. Yang IW, Chou CC, Yung BYM (1996) Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn Schmiedebergs Arch Pharmacol 354: 102-108. Impact Factor: 2.558

  19. Chou CC, Yung BYM (1997) Antiapoptotic effect of Ras in the apoptosis induced by serum deprivation and exposure to actinomycin D. Naunyn Schmiedebergs Arch Pharmacol 355: 177-182. Impact Factor: 2.558

  20. Hsu CY, Yung BYM (1998) Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. Oncogene 16: 915-923. Impact Factor: 7.519

  21. Liu WH, Yung BYM (1998) Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate-induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23. Oncogene 17: 3055-3064. Impact Factor: 7.519

  22. Wu HL, Hsu CY, Liu WH, Yung BYM (1999) Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. Int J Cancer 81: 923-929. Impact Factor: 6.513

  23. Jiang PS, Yung BYM (1999) Down-regulation of nucleophosmin/B23 mRNA delays the entry of cells into mitosis. Biochem Biophys Res Commun 257: 865-870. Impact Factor: 2.466

  24. Liu HT, Yung BYM (1999) In vivo interaction of nucleophosmin/B23 and protein C23 during cell cycle progression in HeLa cells. Cancer Lett 144: 45-54. Impact Factor: 6.375

  25. Liu WH, Hsu CY, Yung BYM (1999) Nucleophosmin/B23 regulates the susceptibility of human leukemia HL-60 cells to sodium butyrate-induced apoptosis and inhibition of telomerase activity. Int J Cancer 83: 765-771. Impact Factor: 6.513

  26. You BJ, Huang IJ, Liu WH, Hung YB, Chang JH, Yung BYM (1999) Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol 360: 683-690. Impact Factor: 2.558

  27. Jiang PS, Chang JH, Yung BYM (2000) Different kinases phosphorylate nucleophosmin/B23 at different sites during G(2) and M phases of the cell cycle. Cancer Lett 153: 151-160. Impact Factor: 6.375

  28. Hsu CY, Yung BYM (2000) Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int J Cancer 88: 392-400. Impact Factor: 6.513
  1. Chou CC, Yung BYM (2001) Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation. Mol Pharmacol 59: 38-45. Impact Factor: 3.922

  2. Huang WH, Yung BYM, Syu WJ, Lee YH (2001) The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication. J Biol Chem 276: 25166-25175. Impact Factor: 4.125

  3. Wu MH, Chang JH, Chou CC, Yung BYM (2002) Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int J Cancer 97: 297-305. Impact Factor: 6.513

  4. Wu MH, Chang JH, Yung BYM (2002) Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 23: 93-100. Impact Factor: 5.105

  5. Wu MH, Yung BYM (2002) UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA. J Biol Chem 277: 48234-48240. Impact Factor: 4.125

  6. Hsu CY, Yung BYM (2003) Involvement of nucleophosmin/B23 in TPA-induced megakaryocytic differentiation of K562 cells. Br J Cancer 89: 1320-1326. Impact Factor: 6.176

  7. Tsui KH, Cheng AJ, Chang P, Pan TL, Yung BYM (2004) Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 64: 839-844. Impact Factor: 2.309

  8. Yung BYM (2004) c-Myc-mediated expression of nucleophosmin/B23 decreases during retinoic acid-induced differentiation of human leukemia HL-60 cells. FEBS Lett 578: 211-216. Impact Factor: 3.902

  9. Chan HJ, Weng JJ, Yung BYM (2005) Nucleophosmin/B23-binding peptide inhibits tumor growth and up-regulates transcriptional activity of p53. Biochem Biophys Res Commun 333: 396-403. Impact Factor: 2.466

  10. Weng JJ, Yung BYM (2005) Nucleophosmin/B23 regulates PCNA promoter through YY1. Biochem Biophys Res Commun 335: 826-831. Impact Factor: 2.466

  11. Chang JT, Wang HM, Chang KW, Chen WH, Wen MC, Hsu YM, Yung BYM, Chen IH, Liao CT, Hsieh LL, Cheng AJ (2005) Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int J Cancer 114: 942-949. Impact Factor: 6.513

  12. Yeh CW, Huang SS, Lee RP, Yung BYM (2006) Ras-dependent recruitment of c-Myc for transcriptional activation of nucleophosmin/B23 in highly malignant U1 bladder cancer cells. Mol Pharmacol 70: 1443-1453. Impact Factor: 3.922

  13. Lin CY, Tsui KH, Yu CC, Yeh CW, Chang PL, Yung BYM (2006) Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 6: 4381-4389. Impact Factor: 4.041

  14. Lin CY, Liang YC, Yung BYM (2006) Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. Cell Signal 18: 2041-2048. Impact Factor: 3.937

  15. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BYM, Lupold SE, Rodriguez R (2006) Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 319: 533-542. Impact Factor: 3.867

  16. Chou CC, Yung BYM, Hsu CY (2007) Involvement of nPKC-MAPK pathway in the decrease of nucleophosmin/B23 during megakaryocytic differentiation of human myelogenous leukemia K562 cells. Life Sci 80: 2051-2059. Impact Factor: 2.936

  17. Liu H, Tan BC, Tseng KH, Chuang CP, Yeh CW, Chen KD, Lee SC, Yung BYM (2007) Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation. EMBO Rep 8: 394-400. Impact Factor: 8.568

  18. Chen CL, Tsui KH, Lin CY, Chang PL, Tang P, Yung BYM (2007) Can probability of genetic mutation be an indicator of clinical relevance? Genomics 90: 746-750. Impact Factor: 2.801
  19. Yung BYM (2007) Oncogenic role of nucleophosmin/B23. Chang Gung Med J 30: 285-293.

  20. Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BYM (2008) Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin 29: 364-370. Impact Factor: 3.223

  21. Lin CY, Tan BC, Liu H, Shih CJ, Chien KY, Lin CL, Yung BYM (2010) Dephosphorylation of nucleophosmin by PP1beta facilitates pRB binding and consequent E2F1-dependent DNA repair. Mol Biol Cell 21: 4409-4417. Impact Factor: 3.685

  22. Weng CH, Yung BYM, Weng JJ, Wu MH (2011) Involvement of nucleophosmin/B23 in the cellular response to curcumin. J Nutr Biochem 22: 46-52. Impact Factor: 4.518

  23. Tran NT, Wang TH, Lin CY, Tsai YC, Lai CH, Tai Y, Yung BYM (2011) Direct synthesis of Rev peptide-conjugated gold nanoparticles and their application in cancer therapeutics. Bioconjug Chem 22: 1394-1401. Impact Factor: 4.818

  24. Tan BC, Yang CC, Hsieh CL, Chou YH, Zhong CZ, Yung BYM, Liu H (2012) Epigeneitc silencing of ribosomal RNA genes by Mybbp1a. J Biomed Sci 19: 57. Impact Factor: 2.799

  25. Yang CC, Liu H, Chen SL, Wang TH, Hsieh CL, Huang Y, Chen SJ, Chen HC, Yung BYM, Chin-Ming Tan B (2012) Epigenetic silencing of myogenic gene program by Myb-binding protein 1a suppresses myogenesis. EMBO J 31: 1739-1751. Impact Factor: 9.792

  26. Tan BC, Yang CC, Hsieh CL, Chou YH, Zhong CZ, Yung BYM, Liu H (2012) Epigenetic silencing of ribosomal RNA genes by Mybbp1a. J Biomed Sci 19: 57. Impact Factor: 2.799

  27. Lo SJ, Fan LC, Tsai YF, Lin KY, Huang HL, Wang TH, Liu H, Chen TC, Huang SF, Chang CJ, Lin YJ, Yung BYM, Hsieh SY (2013) A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells. Hepatology 57: 1893-1905. Impact Factor: 13.246

  28. Chan LWC, Lin XH, Yung G, Lui T, Chiu YM, Wang FF, Tsui NBY, Cho WCS, Yip SP, Siu PM, Wong SCC, Yung BYM (2015) Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia. Sci Rep 5: 10973. Impact Factor: 4.122 Ranking:12/64